Sign In

Dori Thomas-Karyat

Dori Thomas-Karyat is the Founder and CEO of Synthis Therapeutics, a biotech company focused on developing innovative cancer treatments.12 She is an expert in immuno-oncology with over 20 years of experience, specializing in TGF-β research.2

Career Background

Dr. Thomas-Karyat's professional journey includes:

  • Working in pharma drug discovery at Abbvie and Roche as a project lead2
  • Completing a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in Dr. Joan Massague's lab2
  • Receiving a Cancer Research Institute Fellowship during her postdoc2
  • Earning a Ph.D. in Immunology from Washington University in St. Louis School of Medicine2

Synthis Therapeutics

Under her leadership, Synthis Therapeutics has achieved several milestones:

  • Winning a pitch competition in late 20231
  • Working on a TGF-β antibody drug conjugate at JLABS' Manhattan location1
  • Demonstrating in vivo efficacy and safety of their lead candidate, SYN1015
  • Securing three issued patents on their platform in the US and Japan5
  • Raising seed funding5
  • Receiving multiple NCI Phase I SBIR Awards3

Dr. Thomas-Karyat and her team were finalists for the XSeed Award in 2024 for their development of SYN301.6 She is based in Jersey City, New Jersey, and is actively involved in the biotech community.4

Highlights

Aug 27 · ewillcure.com
Spotlight on XSeed Award Finalist: Dori Thomas-Karyat, PhD ... - Cure
Spotlight on XSeed Award Finalist: Dori Thomas-Karyat, PhD ... - Cure

Related Questions

What inspired Dori Thomas-Karyat to start Synthis Therapeutics?
What are the key achievements of Dori Thomas-Karyat in the immuno-oncology field?
How did winning the pitch competition impact Synthis Therapeutics?
What is the significance of the TGF-β antibody drug conjugate in Synthis' research?
What are the main challenges Dori Thomas-Karyat has faced in her career?
Dori Thomas-Karyat
Dori Thomas-Karyat, photo 1
Dori Thomas-Karyat, photo 2
Add to my network

Location

Greater New York City Area